Navigation Links
Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
Date:11/15/2010

ient compared with 4.5 days per patient in the placebo group. This finding is especially noteworthy because heart failure is the leading cause of hospitalization in Americans 65 and older.

Additionally, the 12-month CUPID data show that heart failure, which is a progressive disease, became stabilized in high dose MYDICAR-treated patients: heart failure symptoms, exercise tolerance, serum biomarkers and cardiac function essentially improved or remained the same while these parameters deteriorated substantially in patients treated with placebo and concurrent optimal drug and device therapy.

"We believe the clear safety and efficacy sustained in patients over a 12-month period strongly support the continued development of MYDICAR for a Phase 3 study and commercialization," said Krisztina Zsebo, Ph.D., President and CEO of Celladon. "The clinical deterioration seen in the placebo patients receiving ongoing optimal standard therapy emphasizes the tremendous unmet medical need in people with advanced heart failure. Based on these results we are encouraged that MYDICAR can fill this need."  

The CUPID Trial

The CUPID trial (Calcium Up-regulation by Percutaneous administration of gene therapy In cardiac Disease) is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of MYDICAR®, a genetically targeted enzyme replacement therapy for advanced heart failure. Enrolled patients had severe forms of the disease defined by New York Heart Association Class III or IV heart failure, significantly impaired pumping function of their hearts (ejection fraction < 35 percent), and less than half the normal ability to transport and utilize oxygen during exercise testing (VO2max < 20 mL/kg/min). The CUPID trial ClinicalTrials.gov Identifier is NCT00454818.

Primary outcome measures included safety, worsening of heart failure leading to hospitalization, f
'/>"/>

SOURCE Celladon Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
2. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
3. Pharmos Corporation Reports 2008 Second Quarter Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. Genaera Corporation Announces Second Quarter Financial Results
6. MannKind Corporation Reports Second Quarter Financial Results
7. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
8. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
9. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
11. Mymetics Corporation Important Shareholders Information Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 PureTech , ... tackling big healthcare problems, announced today the closing ... with participation from Invesco Perpetual, a $120 Billion ... to drive PureTech,s existing pipeline forward and to ... has the scientific creativity to really go for ...
(Date:10/19/2014)... Latin American hardware encryption display market report defines and ... forecast of revenue. This market was valued at $165.0 ... million by 2018, at a CAGR of 70.3% from ... the Latin American hardware encryption market report to get ... provides a glimpse of the segmentation of the market, ...
(Date:10/19/2014)... 2014 The Asian Automatic patient billing ... analysis and forecast of revenue. The Automatic patient billing ... $463.9 million by 2018, at a developing CAGR of ... TOC of the Asian Automatic patient billing market, to ... also provides a glimpse of the segmentation of this ...
(Date:10/19/2014)... October 19, 2014 The report ... & Homeland Security), Technology, Payload, Type & by ... segments the global unmanned ground vehicle market into ... forecasting of market sizes. The report also identifies ... opportunities impacting it along with the adoption trends. ...
Breaking Biology Technology:PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 2Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 5
... Zyngenia , Inc ... drugs called Zybodies™, announced today that it has promoted ... and appointed Daniel L. Menichella as Chief ... start in September 2009, Zyngenia has made tremendous progress in both ...
... Silence Therapeutics plc (AIM: SLN) ("Silence" or the ... company, announces that the United States Patent and Trademark Office ... that form part of the foundational "Zamore Design Rule" patent ... during 2010, the USPTO has concluded that the reissued claims ...
... and MONTREAL, Dec. 9, 2011 ICBS Ltd., (OTCPK: ICBT), updates ... concentrating on three partnership entities that we feel have the ... Solutions and Identascan. In each instance, ICBS has ... companies to move forward in their goals. We have paid ...
Cached Biology Technology:Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 2Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer 3Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents 2Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents 3Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents 4ICBS, Update for Shareholders. 2ICBS, Update for Shareholders. 3
(Date:10/16/2014)... cultivated efficiently, they are anything but sustainable: environmental ... cultivation is becoming increasingly evident. Despite their disadvantages, ... are regarded as the sole possibility of achieving ... finds Bernhard Schmid, an ecology professor at the ... of agriculture and forestry. After all, a new ...
(Date:10/15/2014)... from strains of influenza virus increases with the latest ... complacent that the most substantial threats have been identified, ... arise when a new virus strain – against which ... in the human population. There have been five such ... which – the 1918 Spanish Flu – cost 50 ...
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... growing mobile commerce market releases photos and video of the recent ... October 13 th . Gino Pereira , ... angel investor Mr. Chad A. Verdi rang the bell.  ... his investors and employees "for their work and dedication in bringing ...
Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
... berries and cherries and other fruits in the United States, ... genome sequencing at the University of California, Davis, and a ... work is expected to accelerate basic and applied research, leading ... Officially published Dec. 1 in the journal G3 ...
... subpolar fjords of Antarctica, researchers from the University ... abundance and diversity at the seafloor. During a ... studied the seafloor communities of glacier dominated fjords ... very rapid climate warming. The scientists ...
... E. Giblin, a senior scientist at the Marine Biological ... American Association for the Advancement of Science (AAAS), the ... journal, Science . Giblin was elected for ... to nitrogen and sulfur cycling in sediments and soils ...
Cached Biology News:Fruit pest targeted by genomic research 2Fruit pest targeted by genomic research 3Antarctic fjords are climate-sensitive hotspots of diversity in a rapidly warming region 2Antarctic fjords are climate-sensitive hotspots of diversity in a rapidly warming region 3
... 200 IS System is ideal for developing ... reagents. This system contains the new, improved, ... Luminex. The user can design specific templates ... system has fully integrated graphing and data ...
...
... GeneSwitch Cell Lines stably express the ... cell line is functionally tested for ... the expression control vector pGene/V5-His/lacZ and ... treatment with mifepristone (Figure 1). These ...
... for 10 separate biopanning experiments, complexity ... gIII Sequencing Primer (100 pmol), for ... Primer (100 pmol), for automated DNA ... Control target (Streptavidin) and Elutant (Biotin), ...
Biology Products: